| 2026-08-04 | Transcript | Q3 FY26 earnings call transcript |
| 2026-08-04 | Press release | Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results |
| 2026-08-04 | Press release | Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-03 | Press release | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 2026-07-22 | Press release | Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients w |
| 2026-07-21 | Press release | Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results |
| 2026-06-29 | Deck | Investor presentation · Jun 2026 |
| 2026-06-22 | Press release | Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Tr |
| 2026-06-18 | Press release | Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R& |
| 2026-06-16 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-02 | Press release | Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events |
| 2026-05-27 | Press release | Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 |
| 2026-05-12 | Deck | Investor presentation · May 2026 |
| 2026-05-12 | Document | View Poster |
| 2026-05-07 | Transcript | ARROWHEAD PHARMACEUTICALS Fiscal 2026 Second Quarter Conference Call – Prepared Remarks |
| 2026-05-07 | Press release | Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results - Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-03-27 | Document | Investor document · Mar 2026 |
| 2026-03-20 | 8-K | Form 8-K, Item 5.07 |
| 2026-02-05 | Transcript | ARROWHEAD PHARMACEUTICALS Fiscal 2026 First Quarter Conference Call – Prepared Remarks |
| 2026-02-05 | Press release | Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results - Conference Call and Webcast Today, February 5, 2026, at 4:30 p.m. ET |
| 2026-02-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-05 | 10-Q | Form 10-Q for the quarter ended Dec 31 |
| 2026-01-27 | Proxy | Definitive proxy statement |
| 2026-01-12 | 8-K | Form 8-K, Item 1.01 |
| 2026-01-09 | 8-K | Form 8-K, Item 1.01 |
| 2026-01-06 | 8-K | Form 8-K, Item 7.01 |
| 2025-12-08 | Deck | Investor presentation · Dec 2025 |
| 2025-12-07 | Deck | Corporate Presentation - December 2025 |
| 2025-12-03 | Document | WCIRDC 2025 SHASTA 3 and 4 Baseline |
| 2025-12-03 | Document | WCIRDC 2025 Recurrent AP |
| 2025-12-03 | Document | WCIRDC 2025 Monte Carlo Simulation |
| 2025-11-30 | Transcript | Q4 FY25 earnings call transcript |
| 2025-11-25 | Press release | Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results |
| 2025-11-25 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-25 | 10-K | Annual report on Form 10-K, FY25 |
| 2025-11-18 | 8-K | Form 8-K, Item 8.01 |